Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386567495> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4386567495 endingPage "54" @default.
- W4386567495 startingPage "44" @default.
- W4386567495 abstract "Platinum is the main component of the most chemotherapy (CT) regimens, but their use may be limited because of nephrotoxicity. Kidney injury molecule 1 (KIM-1) is considered as an early marker of cisplatininduced acute kidney injury (AKI). The aim of our study was to evaluate the changes in the burinary levels of KIM-1 (uKIM-1) in cancer patients receiving nephrotoxic CT throughout the entire course of the treatment. Material and Methods . The level of uKIM-1 was determined by enzyme immunoassay in untreated 19 patients with solid malignancies before each CT cycle (regimens with cisplatin or oxaliplatin) and every next day after cytostatic drugs administration. uKIM-1 values were normalized to urinary creatinine concentration (uKIM-1). The kidneys function was assessed by the serum creatinine (sCr) and glomerular fltration rate (GFR) value. Results . According to laboratory parameters, renal function in patients before treatment corresponded to normal ranges. During CT, an increase in sCr by more than 50 % (decrease in GFR to 68 ml/min/1.73 m 2 ), which corresponded to stage I AKI (KDIGO) was revealed in one patient (5.3 %) only. uKIM-1 levels before CT were above the upper limit of normal range (3.4 ng/mg uCr ) in 3 patients (15.8 %; median 2.1 ng/mg uCr ); at the beginning of the 2nd cycle of CT they were increased in 9 patients (47.4 %; median 3.2 ng/mg uCr ; p=0.0025, Mann-Whitney test); at the beginning of the 3rd cycle of CT uKIM-1 levels were increased in 12 patients (63.2 %; median 4.9 ng/mg uCr ; p=0.00007). During CT with cisplatin the average level of uKIM-1 increased with each subsequent cycle, in most cases it increased already the day after the administration of cytostatic drugs. No increase in uKIM-1 levels was observed during treatment with oxaliplatin-based regimens. The achievement of the threshold uKIM-1 level of 6.0 ng/mg uCr at the beginning of the next cycle of CT was signifcantly associated with a high risk of its further increase (RR=18.8; p=0.0051). Conclusion . An increase in the level of uKIM-1 after cisplatin administration can be regarded as a marker of subclinical kidney damage. In the future, the increase in uKIM-1 level at the beginning of the cycle of CT may be a reason for enhanced preventive measures or the appointment of less nephrotoxic treatment regimens." @default.
- W4386567495 created "2023-09-10" @default.
- W4386567495 creator A5000393869 @default.
- W4386567495 creator A5000971891 @default.
- W4386567495 creator A5010157736 @default.
- W4386567495 creator A5038573867 @default.
- W4386567495 creator A5052911447 @default.
- W4386567495 creator A5054270519 @default.
- W4386567495 creator A5074567345 @default.
- W4386567495 creator A5080127289 @default.
- W4386567495 creator A5081523614 @default.
- W4386567495 date "2023-09-05" @default.
- W4386567495 modified "2023-09-27" @default.
- W4386567495 title "Dynamics of urinary kim-1 as a biomarker of acute kidney injury in cancer patients undergoing cisplatin-based chemotherapy" @default.
- W4386567495 doi "https://doi.org/10.21294/1814-4861-2023-22-4-44-54" @default.
- W4386567495 hasPublicationYear "2023" @default.
- W4386567495 type Work @default.
- W4386567495 citedByCount "0" @default.
- W4386567495 crossrefType "journal-article" @default.
- W4386567495 hasAuthorship W4386567495A5000393869 @default.
- W4386567495 hasAuthorship W4386567495A5000971891 @default.
- W4386567495 hasAuthorship W4386567495A5010157736 @default.
- W4386567495 hasAuthorship W4386567495A5038573867 @default.
- W4386567495 hasAuthorship W4386567495A5052911447 @default.
- W4386567495 hasAuthorship W4386567495A5054270519 @default.
- W4386567495 hasAuthorship W4386567495A5074567345 @default.
- W4386567495 hasAuthorship W4386567495A5080127289 @default.
- W4386567495 hasAuthorship W4386567495A5081523614 @default.
- W4386567495 hasBestOaLocation W43865674951 @default.
- W4386567495 hasConcept C121608353 @default.
- W4386567495 hasConcept C126189478 @default.
- W4386567495 hasConcept C126322002 @default.
- W4386567495 hasConcept C126894567 @default.
- W4386567495 hasConcept C143998085 @default.
- W4386567495 hasConcept C159641895 @default.
- W4386567495 hasConcept C185592680 @default.
- W4386567495 hasConcept C2776694085 @default.
- W4386567495 hasConcept C2778239845 @default.
- W4386567495 hasConcept C2778653478 @default.
- W4386567495 hasConcept C2780091579 @default.
- W4386567495 hasConcept C2780306776 @default.
- W4386567495 hasConcept C2780472472 @default.
- W4386567495 hasConcept C2780962732 @default.
- W4386567495 hasConcept C2781197716 @default.
- W4386567495 hasConcept C526805850 @default.
- W4386567495 hasConcept C54847362 @default.
- W4386567495 hasConcept C55493867 @default.
- W4386567495 hasConcept C71924100 @default.
- W4386567495 hasConcept C77411442 @default.
- W4386567495 hasConceptScore W4386567495C121608353 @default.
- W4386567495 hasConceptScore W4386567495C126189478 @default.
- W4386567495 hasConceptScore W4386567495C126322002 @default.
- W4386567495 hasConceptScore W4386567495C126894567 @default.
- W4386567495 hasConceptScore W4386567495C143998085 @default.
- W4386567495 hasConceptScore W4386567495C159641895 @default.
- W4386567495 hasConceptScore W4386567495C185592680 @default.
- W4386567495 hasConceptScore W4386567495C2776694085 @default.
- W4386567495 hasConceptScore W4386567495C2778239845 @default.
- W4386567495 hasConceptScore W4386567495C2778653478 @default.
- W4386567495 hasConceptScore W4386567495C2780091579 @default.
- W4386567495 hasConceptScore W4386567495C2780306776 @default.
- W4386567495 hasConceptScore W4386567495C2780472472 @default.
- W4386567495 hasConceptScore W4386567495C2780962732 @default.
- W4386567495 hasConceptScore W4386567495C2781197716 @default.
- W4386567495 hasConceptScore W4386567495C526805850 @default.
- W4386567495 hasConceptScore W4386567495C54847362 @default.
- W4386567495 hasConceptScore W4386567495C55493867 @default.
- W4386567495 hasConceptScore W4386567495C71924100 @default.
- W4386567495 hasConceptScore W4386567495C77411442 @default.
- W4386567495 hasIssue "4" @default.
- W4386567495 hasLocation W43865674951 @default.
- W4386567495 hasOpenAccess W4386567495 @default.
- W4386567495 hasPrimaryLocation W43865674951 @default.
- W4386567495 hasRelatedWork W2025464329 @default.
- W4386567495 hasRelatedWork W2093874596 @default.
- W4386567495 hasRelatedWork W2124543160 @default.
- W4386567495 hasRelatedWork W2127896754 @default.
- W4386567495 hasRelatedWork W2366527240 @default.
- W4386567495 hasRelatedWork W2395193492 @default.
- W4386567495 hasRelatedWork W2566477261 @default.
- W4386567495 hasRelatedWork W2981879786 @default.
- W4386567495 hasRelatedWork W3011378569 @default.
- W4386567495 hasRelatedWork W3106404160 @default.
- W4386567495 hasVolume "22" @default.
- W4386567495 isParatext "false" @default.
- W4386567495 isRetracted "false" @default.
- W4386567495 workType "article" @default.